PRESS RELEASE published on 02/29/2024 at 22:05, 2 years 3 months ago Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
PRESS RELEASE published on 02/14/2024 at 13:30, 2 years 4 months ago Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
PRESS RELEASE published on 12/21/2023 at 14:00, 2 years 6 months ago Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
PRESS RELEASE published on 12/14/2023 at 22:15, 2 years 6 months ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRESS RELEASE published on 10/31/2023 at 12:30, 2 years 7 months ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
PRESS RELEASE published on 10/25/2023 at 13:30, 2 years 7 months ago Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
PRESS RELEASE published on 10/17/2023 at 14:00, 2 years 8 months ago Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
PRESS RELEASE published on 09/20/2023 at 13:30, 2 years 9 months ago Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Published on 06/24/2026 at 00:00, 1 hour 14 minutes ago Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 1 hour 29 minutes ago Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 1 hour 54 minutes ago BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 1 hour 59 minutes ago EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects
Published on 06/23/2026 at 23:00, 2 hours 14 minutes ago International Battery Metals Ltd. Announces RSU Grant
Published on 06/23/2026 at 22:20, 2 hours 53 minutes ago Saudi Properties Portal to Accept Applications for Foreign Real Estate Ownership
Published on 06/23/2026 at 20:15, 4 hours 59 minutes ago EQS-Adhoc: OHB SE resolves on the issue of 1,605,388 new shares representing the first tranche of the up to 8.86% capital increase with subscription rights
Published on 06/23/2026 at 18:30, 6 hours 44 minutes ago IEVA GROUP: COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ANNUELLE DU 23 JUIN 2026
Published on 06/23/2026 at 17:55, 7 hours 18 minutes ago ABO Energy ABO Energy drives strategic development and future financing solution forward
Published on 06/23/2026 at 19:47, 5 hours 26 minutes ago GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 5 hours 26 minutes ago GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 6 hours 3 minutes ago GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 6 hours 3 minutes ago GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 18:32, 6 hours 41 minutes ago Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix